Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model
- 1 December 2003
- journal article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 6 (4) , 272-280
- https://doi.org/10.1038/sj.pcan.4500676
Abstract
Extracellular proteases are recognized as critical factors in the progression of a number of carcinomas, including prostate cancer. Matrix metalloproteases (MMP) are important in processes of tumor growth, invasion and dissemination, but other classes of proteases, such as serine and cysteine proteases, also contribute. We utilized the TRAMP model for prostate cancer to elucidate proteases involved in prostate cancer progression. General proteomic analysis was performed on normal murine prostate, early TRAMP tumors and advanced TRAMP tumors, as well as normal and involved lymph nodes. Zymography and antigenic analyses revealed increased expression of mainly pro-MMP in early TRAMP tumors but substantial elaboration of activated MMP only in late TRAMP tumors. Progressive increase in cysteine, serine and certain membrane-bound proteases from normal to early to advanced prostate tumors, was also seen. Our results implicate pericellular proteases as initiators of major proteolytic cascades during tumor progression and suggest targets for maximal therapeutic effect.Keywords
This publication has 17 references indexed in Scilit:
- Clarification of the active gelatinolytic sites in human ovarian neoplasms using in situ zymographyHuman Pathology, 2001
- Cellular Localization of Membrane-type Serine Protease 1 and Identification of Protease-activated Receptor-2 and Single-chain Urokinase-type Plasminogen Activator as SubstratesJournal of Biological Chemistry, 2000
- Treatment with soybean-derived Bowman Birk inhibitor increases serum prostate-specific antigen concentration while suppressing growth of human prostate cancer xenografts in nude miceThe Prostate, 1999
- Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working GroupJournal of Clinical Oncology, 1999
- Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: implications for paracrine growthThe Journal of Pathology, 1999
- Human Kallikrein 2 (hK2) and Prostate-Specific Antigen (PSA): Two Closely Related, but Distinct, Kallikreins in the ProstateCritical Reviews in Clinical Laboratory Sciences, 1998
- Urokinase-Type Plasminogen Activator Expression in Human Prostate CarcinomasThe Lancet Healthy Longevity, 1996
- Prostate cancer in a transgenic mouse.Proceedings of the National Academy of Sciences, 1995
- Prevention of metastasis by inhibition of the urokinase receptor.Proceedings of the National Academy of Sciences, 1993
- Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract.The Journal of cell biology, 1991